Prolonged release suspension for injection 400mg

LSCFT initiation only.

Schizophrenia in adult patients stabilised on oral aripiprazole. 

Application from RMO to be sent to Chief Pharmacist and Medical Director requesting its use.

When prescribing, dispensing, or administering, check that the correct preparation is used—the preparation usually used in hospital for the rapid control of an acute episode (solution for injection containing aripiprazole 7.5 mg/mL) should not be confused with depot preparations (powder and solvent for prolonged-release suspension for injection), which are usually used in the community or clinics for maintenance treatment.

Injection 20mg/1mL, 40mg/2mL
Concentrate injection 50mg/0.5mL, 100mg/1mL

Maintenance in schizophrenia and other psychoses. 

Maintenance in schizophrenia and other psychoses. 

Licensed product no longer available. Where patients have deteriorated following a switch to an alternative depot antipsychotic a request can be made to use the unlicensed product should be made to the Lead Pharmacist in the locaility. 

Injection 50mg/1mL, 100mg/1mL

Maintenance in schizophrenia and other psychoses.

When prescribing, dispensing or administering, check that this is the correct preparation—this preparation is used for maintenance treatment and should not be used for the rapid control of an acute episode.

Pre-filled syringes 50mg, 75mg, 100mg, 150mg - monthly injection

Pre-filled syringes 175mg, 263mg, 350mg, 525mg (Trevicta) - 3-monthly injection

 Pre-filled syringes 700mg, 1000mg (Byannli) - 6-monthly injection

LSCFT initiation only.

Maintenance treatment of schizophrenia in adult patients.

For the monthly injection (Xeplian) and for Aripiprazole LAI: Application from RMO to be sent to Chief Pharmacist and Medical Director requesting its use.

The three monthly injection (Trevicta) if approval has been given for the monthly paliperidone depot there is no requirement for a further request to be sent to request a move to the three monthly option.

Schizophrenia. 

Licensed product no longer available. Where patients have deteriorated following a switch to an alternative depot antipsychotic a request can be made to use the unlicensed product should be made to the Lead Pharmacist in the locaility.

Injection 25mg, 37.5mg, 50mg

Schizophrenia.

Nonformulary in LSCFT.

Consultant psychiatrist initiation only.
Request from doctor must be sent to chief pharmacist and medical director of LSCFT before authorised to prescribe.

Injection 200mg/1mL
Concentrate injection 500mg/1mL

Maintenance in schizophrenia and other psychoses.

When prescribing, dispensing, or administering, check that this is the correct preparation—this preparation is used for maintenance treatment and should not be used for the short-term management of an acute episode.

Zuclopenthixol decanoate has been confused with zuclopenthixol acetate; care must be taken to ensure the correct drug is prescribed and dispensed.